Written Question·Department of Health and Social Care·UIN 109130
Prostate Cancer: Abiraterone
Tabled: 28 January 2026
Answered: 3 February 2026
Question
Wendy Morton
Conservative — Aldridge-Brownhills
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what arrangements are in place to monitor patient outcomes following the expanded use of abiraterone at earlier stages of prostate cancer; and whether those outcomes wil
Answer
Dr Zubir AhmedApproximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prost...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 109130) →